Hospital medicine venture Cogent HMG said it has been chosen to run an intensive care program at the 395-bed Saint Francis Hospital in Delaware. Cogent's Intensivist Group division — which it bought last summer — is running the program at Saint Francis, which is part of the Catholic Health East network.

As it speeds toward the completion of its sale to private-equity titan Blackstone, Emdeon has in the past week brought to a conclusion three similar shareholder lawsuits, two of them in Middle Tennessee, another in chancery court in Delaware.

Massachusetts-based behavioral health care operator PHC has wrapped up its purchase of a Delaware facility that add about $15 milion in annual revenues. PHC, which Joey Jacobs-led Acadia Healthcare is in the process of buying, also has applied to expand the MeadowWood center in New Castle, Del., by two-thirds.

Getahn Ward at The Tennessean has this report today on questions about MedSolutions' denials of certain heart tests for patients in Delaware. MedSolutions' client BlueCross BlueShield of Delaware was "found to have violated state law in its home state by giving the third-party contractor financial incentives to deny doctors’ requests for certain heart tests."

The combined offering will include NiQ's CarePlus™ message-based nurse call system, Dalcon's VoIP-based voice talkback to patient rooms, and the Dalcon Alert™ solution that sends patient care notifications to wireless devices. "Dalcon is a trusted provider of advanced communication technology and services for the healthcare industry nationwide," said Chris Clabaugh, Vice President of Business Development, NiQ. "The combination of CarePlus advanced message and workflow nurse call systems with Dalcon's world class services and communication technology should prove extremely attractive to acute care and aged care facilities of all sizes. We look forward to partnering with them to deliver our combined solutions."

“While we are disappointed in the jury's decision on two of the three patents, the entire matter is not yet resolved,” Ryan said. “We believe that RyMed will be vindicated as these proceedings continue to move through the court system. In the meantime, we expect that the availability of our products will not be affected by this verdict.”